The Drug Delivery Partnering
Terms and Agreements report provides comprehensive understanding and
unprecedented access to the drug delivery partnering deals and agreements
entered into by the worlds leading healthcare companies
Description
The Drug Delivery Partnering Terms
and Agreements report provides comprehensive understanding and unprecedented
access to the drug delivery partnering deals and agreements entered into by the
worlds leading healthcare companies.
The report provides a detailed
understanding and analysis of how and why companies enter drug delivery
partnering deals. The majority of deals are discovery or development stage
whereby the licensee obtains a right or an option right to license the
licensors drug delivery technology. These deals tend to be multicomponent,
starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a
prospective partner’s negotiated deals terms provides critical insight into the
negotiation process in terms of what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of
the payments clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases do
not.
This report contains over 2,000
links to online copies of actual drug delivery deals and contract documents
where available as submitted to the Securities Exchange Commission by companies
and their partners. Contract documents provide the answers to numerous questions
about a prospective partner’s flexibility on a wide range of important issues,
many of which will have a significant impact on each party’s ability to derive
value from the deal.
The drug delivery technology
includes the following sub-technology areas:
- Drug Delivery
- Bioavailability
- Implanatable
- Oral delivery
- Rapid release
- Delayed release
- Parenteral
- Infusion
- Injectable
- Pro-drug
- Targeted
- Tropical
- Transdermal
- Buccal
- Inhaled
- Nasal
- Ocular
- Rectal
- Sublingual
- Urogenital
The initial chapters of this
report provide an orientation of drug dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an
overview of the trends in drug delivery dealmaking since 2009, including
details of average headline, upfront, milestone and royalty terms. Chapter 2
also contains case studies providing an insight into how companies enter into
drug delivery dealmaking.
Chapter 3 provides a review of the
leading drug delivery deals since 2009. Deals are listed by headline value,
signed by big pharma, big biotech, and most active of all biopharma companies.
Where the deal has an agreement contract published at the SEC a link provides
online access to the contract.
Chapter 4 provides a comprehensive
listing of the top 50 big pharma companies with a brief summary followed by a
comprehensive listing of drug delivery deals, as well as contract documents
available in the public domain. Where available, each deal title links via Weblink
to an online version of the actual contract document, providing easy access to
each contract document on demand.
Chapter 5 provides a comprehensive
listing of the top 50 big biotech companies with a brief summary followed by a
comprehensive listing of drug delivery deals, as well as contract documents
available in the public domain. Where available, each deal title links via
Weblink to an online version of the actual contract document, providing easy
access to each contract document on demand.
Chapter 6 provides a comprehensive
and detailed review of drug delivery partnering deals signed and announced
since 2009, where a contract document is available in the public domain. The
chapter is organized by company A-Z, stage of development at signing, deal type
(collaborative R&D, co-promotion, licensing etc), and specific therapy
focus. Each deal title links via Weblink to an online version of the deal
record and the contract document, providing easy access to each contract
document on demand.
Chapter 7 provides a comprehensive
and detailed review of drug delivery partnering deals organized by specific
drug delivery technology type. Each deal title links via Weblink to an online
version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
The report also includes numerous
tables and figures that illustrate the trends and activities in drug delivery
partnering and dealmaking since 2009.
In addition, a comprehensive
appendix is provided organized by drug delivery partnering company A-Z, deal
type definitions and drug delivery partnering agreements example. Each deal
title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each contract
document on demand.
In conclusion, this report
provides everything a prospective dealmaker needs to know about partnering in
the research, development and commercialization of drug delivery technologies
and products.
Drug Delivery Partnering Terms and
Agreements is intended to provide the reader with an in-depth understanding and
access to drug delivery trends and structure of deals entered into by leading
companies worldwide.
Drug Delivery Partnering Terms
and Agreements includes:
- Trends in drug delivery dealmaking in the biopharma industry since 2009
- Analysis of drug delivery deal structure and contract documents
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life drug delivery deals
- Access to over 2,000 drug delivery deals announced
- The leading drug delivery deals by value since 2009
- Most active drug delivery dealmakers since 2009
- The leading drug delivery partnering resources
In Drug Delivery Partnering
Terms and Agreements, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each deal title links via Weblink
to an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
Benefits
Drug Delivery Partnering Terms and
Agreements provides the reader with the following key benefits:
- In-depth understanding of drug delivery deal trends since 2009
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of drug delivery agreements with numerous real life case studies
- Comprehensive access to over 2,000 actual drug delivery deals entered into by the world’s biopharma companies, together with contract documents where available
- Detailed access to actual drug delivery contracts enter into by the leading fifty big pharma and big biotech companies
- Identify leading drug delivery deals by value since 2009
- Identify the most active drug delivery dealmakers since 2009
- Insight into the terms included in a drug delivery agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 2879 pages and 39 Figures “Drug Delivery Partnering Terms and
Agreements” report Covering Executive Summary, Introduction, Trends in drug
delivery dealmaking, Leading drug delivery deals, Big pharma drug delivery
deals, Big biotech drug delivery deals, Drug delivery partnering contracts
directory, Drug delivery dealmaking by technology type, Appendix.
Know more
about this report at – http://mrr.cm/45K
Find all Biotechnology Reports
at: http://www.marketresearchreports.com/biotechnology
No comments:
Post a Comment
Note: only a member of this blog may post a comment.